Interaction between α-MSH and acetylcholinergic system upon striatal cAMP and IP3 levels

被引:8
作者
Cremer, MC [1 ]
de Barioglio, SR [1 ]
Celis, ME [1 ]
机构
[1] Natl Univ Cordoba, Fac Ciencias Quim, Dept Farmacol, Lab Fisiol, RA-5000 Cordoba, Argentina
关键词
D O I
10.1016/S0196-9781(00)00192-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction between the neuropeptide alpha-MSH and the acetylcholinergic system as reflected by changes in cAMP and inositol 1-3-5 triphosphate(IP3)production was investigated in an in vitro model of striatal slices. The possible involvement of D-1 receptors in cholinergic and alpha-MSH- stimulated cAMP and IP3 production in slices of rat striatum was also examined, because it has been demonstrated that acetylcholinergic drugs induce endogenous dopamine release in the striatum. alpha-MSH, pilocarpine(PL) and the selective muscarinic M1 agonist McN-A-343 increased cAMP and IP3 striatal levels, effects blocked by the D-1 antagonist SCH-23390, except for the effects of alpha-MSH on IP3. The muscarinic M-2 antagonist gallamine (GL) brought about an increase in cAMP levels, an effect blocked by SCH-23390. The M-1 antagonist pirenzepine (Pz) induced a decrease both in cAMP and IP3 content, and the nicotinic antagonist di-hydro-beta-eritroidine(DBE) only diminished cAMP production. When alpha-MSH and cholinergic agents were simultaneously added, cAMP and IP3 levels were modified with respect to the values reached when these agents were added alone. An interaction between the acetylcholinergic system and alpha-MSH through M-1 and nicotinic receptors was also observed, These results suggest that the intracellular signaling pathways related to cAMP and IP3 production gated by alpha-MSH and these cholinergic receptors are probably related, alpha-MSH striatum cAMP IP3 muscarinic and nicotinic receptors an in vitro model. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:699 / 704
页数:6
相关论文
共 41 条
[31]   RECOGNITION OF CHOLINERGIC AGONISTS BY THE MUSCARINIC RECEPTOR .2. PILOCARPINE [J].
SCHULMAN, JM ;
PECK, RC ;
DISCH, RL .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (04) :1455-1459
[32]   MUSCARINIC ACTIVITY OF THE THIOLACTONE, LACTAM, LACTOL, AND THIOLACTOL ANALOGS OF PILOCARPINE AND A HYPOTHETICAL MODEL FOR THE BINDING OF AGONISTS TO THE M1 RECEPTOR [J].
SHAPIRO, G ;
FLOERSHEIM, P ;
BOELSTERLI, J ;
AMSTUTZ, R ;
BOLLIGER, G ;
GAMMENTHALER, H ;
GMELIN, G ;
SUPAVILAI, P ;
WALKINSHAW, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (01) :15-27
[33]  
TATRO JB, 1993, METHODS NEUROSCI, V5, P87
[34]   CHOLINERGIC MEDIATION IN THE VENTRAL TEGMENTAL AREA OF ALPHA-MELANOTROPIN INDUCED EXCESSIVE GROOMING - CHANGES OF THE DOPAMINE ACTIVITY IN THE NUCLEUS ACCUMBENS AND CAUDATE PUTAMEN [J].
TORRE, E ;
CELIS, ME .
LIFE SCIENCES, 1988, 42 (17) :1651-1657
[35]  
TORRE E, 1989, ACTA PHYSIOL PHARM L, V39, P49
[36]  
Wang HY, 1995, MOL PHARMACOL, V48, P988
[37]   EXPRESSION OF MUSCARINIC ACETYLCHOLINE AND DOPAMINE RECEPTOR MESSENGER-RNAS IN RAT BASAL GANGLIA [J].
WEINER, DM ;
LEVEY, AI ;
BRANN, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) :7050-7054
[38]   MUSCARINIC ACETYLCHOLINE-RECEPTORS - STRUCTURAL BASIS OF LIGAND-BINDING AND G-PROTEIN COUPLING [J].
WESS, J ;
BLIN, N ;
MUTSCHLER, E ;
BLUML, K .
LIFE SCIENCES, 1995, 56 (11-12) :915-922
[39]  
WOOD PL, 1979, J PHARMACOL EXP THER, V209, P97
[40]   DIFFERENTIAL-EFFECTS OF M1-MUSCARINIC AND M2-MUSCARINIC DRUGS ON STRIATAL DOPAMINE RELEASE AND METABOLISM IN FREELY MOVING RATS [J].
XU, M ;
MIZOBE, F ;
YAMAMOTO, T ;
KATO, T .
BRAIN RESEARCH, 1989, 495 (02) :232-242